NCT02274155 - Anti-OX40 Antibody in Head and Neck Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2014

Primary Completion Date

September 17, 2017

Study Completion Date

December 21, 2023

Conditions

Head and Neck Cancer

Interventions

DRUG

Anti-OX40 antibody administration

Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study

PROCEDURE

Surgical Resection

Surgical Resection of Tumor

Trial Locations (1)

Portland Providence Medical Center, Portland